Analyzing R&D Budgets: Axsome Therapeutics, Inc. vs Ligand Pharmaceuticals Incorporated

R&D Spending: Axsome's Surge vs. Ligand's Stability

__timestampAxsome Therapeutics, Inc.Ligand Pharmaceuticals Incorporated
Wednesday, January 1, 2014427920012122000
Thursday, January 1, 2015677698713380000
Friday, January 1, 20162119986021221000
Sunday, January 1, 20171995761626887000
Monday, January 1, 20182349505527863000
Tuesday, January 1, 20195364706755908000
Wednesday, January 1, 20207024457959392000
Friday, January 1, 20215806072569012000
Saturday, January 1, 20225794744736082000
Sunday, January 1, 20239794400024537000
Monday, January 1, 2024187077000
Loading chart...

Unleashing insights

R&D Investment Trends: Axsome Therapeutics vs. Ligand Pharmaceuticals

In the competitive landscape of pharmaceuticals, research and development (R&D) spending is a critical indicator of innovation and future growth. Over the past decade, Axsome Therapeutics, Inc. and Ligand Pharmaceuticals Incorporated have shown distinct trajectories in their R&D investments. Starting in 2014, Ligand led with a 65% higher R&D budget compared to Axsome. However, by 2023, Axsome's R&D spending surged by over 2,000%, surpassing Ligand by nearly 300%. This dramatic increase highlights Axsome's aggressive push towards innovation, potentially positioning it as a future leader in the industry. Meanwhile, Ligand's R&D expenses peaked in 2021, reflecting a more stable investment strategy. These trends underscore the dynamic nature of pharmaceutical R&D, where strategic investments can significantly alter a company's competitive edge.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025